Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)
Sutro Biopharma (STRO) posted Cash from Operations of 26435000.0 for Q4 2025, up 30.78% sequentially from 38189000.0 in Q3 2025, and up 63.15% YoY from 16202818.07 in Q4 2024.
Sutro Biopharma (STRO) Cash from Operations (2017 - 2025) Analysis & Trends
Sutro Biopharma has reported Cash from Operations for 9 years, with the latest figure at 26435000.0 in Q4 2025.
- Quarterly Cash from Operations rose 63.15% year-over-year to 26435000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 177231000.0 (up 7.47% YoY) and the FY2025 annual result came in at 177231000.0, up 7.47% from the prior year.
- Cash from Operations climbed to 26435000.0 in Q4 2025 per STRO's latest filing, from 38189000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 65854000.0 in Q3 2022 and troughed at 71738000.0 in Q4 2024.
- A 5-year average of 27925850.0 and a median of 30812500.0 in 2021 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 369.83% in 2022, then slumped 879.13% in 2023.
- Over 5 years, Cash from Operations stood at 21580000.0 in 2021, then declined by 10.58% to 23864000.0 in 2022, then soared by 158.97% to 14072000.0 in 2023, then plunged by 609.79% to 71738000.0 in 2024, then surged by 63.15% to 26435000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 26435000.0, 38189000.0, and 44724000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -26.44 Mn |
| Dec 31, 2025 | -26.44 Mn |
| Sep 30, 2025 | -38.19 Mn |
| Sep 30, 2025 | -38.19 Mn |
| Jun 30, 2025 | -44.72 Mn |
| Jun 30, 2025 | -44.72 Mn |
| Mar 31, 2025 | -67.88 Mn |
| Mar 31, 2025 | -67.88 Mn |
| Dec 31, 2024 | -71.74 Mn |
| Dec 31, 2024 | -71.74 Mn |
| Sep 30, 2024 | -64.52 Mn |
| Sep 30, 2024 | -64.52 Mn |
| Jun 30, 2024 | 9.46 Mn |
| Jun 30, 2024 | 9.46 Mn |
| Mar 31, 2024 | -64.74 Mn |
| Mar 31, 2024 | -64.74 Mn |
| Dec 31, 2023 | 14.07 Mn |
| Dec 31, 2023 | 14.07 Mn |
| Sep 30, 2023 | -33.50 Mn |
| Sep 30, 2023 | -33.50 Mn |